What's a Drug Worth?

The transcript discusses the complexities of value-based contracts in the pharmaceutical industry, focusing on challenges like data collection, defining value, and pricing unique drugs. It highlights the role of independent bodies like ICER in determining drug value and explores policy suggestions to improve competition and pricing. The discussion also covers the international pricing index and its implications for the U.S. market, concluding with future prospects for outcome-based pricing and innovative treatments.

What are the implications of high-cost drugs on insurance premiums and the overall healthcare system?

What are the challenges faced by pharmaceutical companies in establishing value-based pricing models?

Discuss the potential impact of government regulation on drug pricing and competition in the pharmaceutical industry.

How can innovative payment structures, such as subscription models, enhance the value of healthcare outcomes?